Mena[superscript calc], a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer
Name
12885_2015_Article_1468.pdf
Size
768 KB
Format
Adobe PDF
Checksum (MD5)
fba78f0df33f20e217db013f0f14ed6b
Author(s)
Forse, Catherine L.
Agarwal, Seema
Pinnaduwage, Dushanthi
Gertler, Frank
Condeelis, John S.
Lin, Juan
Xue, Xiaonan
Johung, Kimberly
Mulligan, Anna Marie
Rohan, Thomas E.
Date Issued
June 2015
Journal
BMC Cancer
Publisher
BioMed Central
Citation
Forse, Catherine L., Seema Agarwal, Dushanthi Pinnaduwage, Frank Gertler, John S. Condeelis, Juan Lin, Xiaonan Xue, et al. “Mena[superscript calc], a Quantitative Method of Metastasis Assessment, as a Prognostic Marker for Axillary Node-Negative Breast Cancer.” BMC Cancer 15, no. 1 (December 2015).
Version
Final published version
Abstract
Background
Mena[superscript calc] is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Mena[superscript calc] and risk of death from breast cancer. Our goal was to determine if Mena[superscript calc] could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer.
Methods
Analysis of the association of Mena[superscript calc] with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Mena[superscript calc] with risk of death after adjustment for HER2 status and clinicopathological tumor features.
Results
High Mena[superscript calc] was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Mena[superscript calc] cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Mena[superscript calc] in the HER2, basal and luminal molecular subtypes.
Conclusions
Mena[superscript calc] may serve as an independent prognostic biomarker for the ANN breast cancer patient population.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1186/s12885-015-1468-6
